The above findings indicated that DLL3 as an emerging potential target for SCLC cells, and the development of DLL3 CAR T-cells towards the anti-tumor activity of DLL3-positive SCLC potentially showed efficient persistence, specificity, and feasibility. This evidence concerns the gene DLL3 and neoplasm.